Kornimate/medical-research-clean huggingface dataset:
brief strategic family therapy for adolescent drug abusers

Conditions: Substance Abuse

Summary: the purpose of this study is to compare brief strategic family therapy (bsft) for adolescent drug abusers to treatment as usual (tau). an additional follow up assessment, funded by an american recovery \& reinvestment act (arra) grant, was completed 5 years post randomization in order to examine the long term effects of outpatient treatments for illicit drug using adolescents.

adolescent drug abuse continues to be one of the most pressing public health issues in the united states-our nation's teenagers continue to use illicit drugs at a worrisome rate. broad reviews of the treatment outcome literature indicate that family interventions in general, and brief strategic family therapy (bsft) in particular, are effective with drug using youth. this study is designed to compare bsft to treatment as usual (tau). the researchers believe that bsft will be much more effective than tau in reducing adolescent drug use. they will also examine which of these treatment approaches does a better job of engaging adolescents and family members in treatment, decreasing problem behaviors, decreasing sexually risky behaviors, increasing pro-social activities (e.g., school, work), and improving the functioning of the family. with the addition of the extended follow up, we have the opportunity to examine the sustainability of study outcomes into early adulthood, filling a gap in the treatment research literature about the long-term effects of adolescent substance abuse treatment. the follow up study examined the long term effectiveness of bsft compared to tau in the rates of substance use, number of arrests and externalizing behaviors, in youth who received study treatments at the time when they were adolescents.

Eligibility criteria:
main study: inclusion criteria: * adolescents ages 12 to 17 * used any illicit drugs (other than alcohol and tobacco) in the 30-day period * live with or intend to live with a formal or informal family exclusion criteria: * suicidal or homicidal ideation. follow up study: inclusion criteria: * youth must have signed consent during the main study to be approached for future research * currently 18 years old or older

Keywords: bsft family therapy adolescents substance abuse
europainclinicsstudy xi (cryo vs rf mb z joints)

Conditions: Back Pain

Summary: determine the efficacy of lumbar medial branch neurotomy by radiofrequency and cryoablation in patients with chronic low back pain

description of the clinical state: facet joint pain encompasses a significant portion of the possible sources of pain in patients with vertebrogenic algic syndrome. a typical symptom caused by facet joint irritation of the medial branch nerve is a back pain with intermittent irregular patchy pain spreading to the legs. the cause of this pain is irritation of the medial branch of the dorsal nerve root which innervates a facet joint. confirmation of the source of the pain involves local anaesthetic blocks of the medial nerve branches in several adjoining vertebral areas. if this test is positive, then the patient's condition is indicated for radiofrequency ablation or cryoablation of the nerve branches. description of interventional procedures: patients with chronic low back pain with confirmed zygapophysial joint pain after previous two medial branch nerve blocks with positive results are indicated for radiofrequency medial neurotomy or alternative cryoablation neurotomy. navigation with probes in both cases is arranged and directed according to fluoroscopic imaging.

Eligibility criteria:
inclusion criteria:dsds * patients aged between 20 and 80 * positive two medial branch nerve blocks with pain relief over 80% during the first 12hours after nerve block application * positive patient history for facet joint pain * patients with chronic low back pain for at least 6 months with back pain and leg pain (vas \>=5) * those who (only if a signature was obtainable), or whose legal guardian, fully understood the clinical trial details and signed the informed consent form exclusion criteria: * patients with a history of other spinal diseases (compression fracture, spondylitis, tumor) * women with positive a pregnancy test before the trial or who planned to become * pregnant within the following 3 years * other patients viewed as inappropriate by the staff * disagreement with participation in the study
electromyography in thoracic outlet syndrome

Conditions: Thoracic Outlet Syndrome

Summary: record the enmg data carried out systematically in patients treated by rehabilitation for thoracic outlet syndrome in order to assess their characteristics and judge the relevance of these data in the context of the diagnosis and their possible modifications following the rehabilitation treatment.


Eligibility criteria:
inclusion criteria: * inpatient rehabilitation for thoracic outlet syndrome * patients' agreement exclusion criteria: * \< 18 years old * not able to consent * pregnancy * musculoskeletal disorders of the upper limbs * acute cardiac, pulmonary, metabolic or neurological diseases

Keywords: thoracic outlet syndrome electromyography neurogenic rehabilitation diagnosis
nemaline myopathy clinical research network (nm-ctrn)

Conditions: Nemaline Myopathy

Summary: the goal of this study is to establish a research network to help define the natural disease history and clinical outcome measures for nemaline myopathy (nm).

the long-term aim of this study is to incorporate these outcome measures into clinical trials for nm therapies. outcome measures to be assessed will be dependent on the participant's age and functional status. follow-up visits will be conducted either every 3 or 6 months, dependent on age, for a total of 3 years.

Eligibility criteria:
inclusion criteria: * 0-18 years of age at recruitment * confirmation of nemaline myopathy (pathogenic or likely pathogenic mutations in acta1 (ad) or neb (ar) * patient and/or parent or legal guardian must be willing and able to provide informed consent exclusion criteria: * clinically significant medical finding on the physical examination, other than nm, that the investigator deems unsuitable for participation in and/or completion of the study procedures * any confirmed chronic or acute condition or disease affecting any system(s), which could interfere with the results of the study and/or the compliance with the study procedures. this will be subject to the clinical judgement of the principal investigator (pi) * participants of ongoing (interventional) clinical trials that assess the efficacy of potential treatments will be excluded * safety concerns

Keywords: neuromuscular disease observational study congenital myopathy nemaline rod
preliminary research using artificial intelligence technology to identify differences in facial expressions between healthy people, patients with cognitive decline, and patients with dementia

Conditions: Artificial Intelligence Technology; Cognitive Decline; Dementia; Identify; Facial Expressions

Summary: through artificial intelligence technology, we have conducted a preliminary study aimed at identifying differences in facial expressions among healthy individuals, patients with cognitive decline, and dementia patients. this research offers a novel method and tool for dementia screening, contributing to effective strategies for dementia prevention in our country. by utilizing this approach, we can effectively delay the onset of disability, promote healthy aging among our elderly population, reduce the caregiving burden on individuals, families, and society, and lower medical expenses.


Eligibility criteria:
inclusion criteria: age between 50 and 75 years. * experimental group: * mci group: cdr score of 0.5 or mmse score between 20-25 (mild/early stage). * dementia group: cdr score greater than 1 or mmse score between 10-19 (moderate/middle stage). * control group: * health group: mmse score of 26 or above. * participants must be conscious and able to follow instructions.

Keywords: artificial intelligence technology cognitive decline dementia
bupivacaine plus diclofenac versus bupivacaine alone for postoperative pain relief in gynecologic cancer patients

Conditions: Post-operative Pain

Summary: compare the postoperative pain between bupivacaine peritoneal infiltration plus immediately postoperative intramuscular diclofenac and bupivacaine peritoneal infiltration alone by using visual analogue score (vas).

the primary objective is to compare the postoperative pain between bupivacaine peritoneal infiltration plus immediately postoperative intramuscular diclofenac and bupivacaine peritoneal infiltration alone by using visual analogue score (vas). the secondary objective is to evaluate the time to first dose and the total amount of morphine requirement after the operation in both groups.

Eligibility criteria:
inclusion criteria: * gynecologic cancer patients ,i.e. cervical cancer, endometrial cancer, or ovarian tumor suspicious for malignancy * who has scheduled for operation via laparotomy route * women who has asa physical status i-ii * all of the have age more than 20 years old * able to communicate in thai * women who agrees to participate in this study exclusion criteria: * patient who had emergency conditions - indication for emergency operation * intraoperative cardiac arrhythmia * operation purpose for only tumor biopsy * women who have abnormal kidney function test (cr \> 1.5) * women with history of gastrointestinal bleeding * women who take the antiplatelet or anticoagulant medications * women with history of allergy to bupivacaine and nsaids * women who cannot evaluated pain score
sound processing changes in babies with opioid exposure

Conditions: Neonatal Abstinence Syndrome

Summary: the purpose of this study is to identify problems with interpreting sounds in babies that have been exposed to opioids prior to birth. being able to identify these issues in infancy may allow us to find children who may have problems with language learning later in life so that we can try to minimize these.

this is a single center prospective study of neonates \>36 weeks' gestation prenatally exposed to psychoactive substances and gestationally age-matched controls. evoked response potentials on eeg in response to auditory oddball paradigms will be compared between cohorts. analyses will try to identify differences in auditory processing using anovas to compare the mismatch negativity measures, amplitudes and latencies as a function of study group.

Eligibility criteria:
inclusion criteria: * gestational age ≥ 36 weeks, confirmation of dates via ultrasound or last menstrual period * prenatal opioid exposure ("exposed"), confirmed via admitted use or newborn drug screen; no prenatal opioid exposure ("control") by maternal report or testing * all races, ethnicities, sexes to be included * informed permission form signed by mother exclusion criteria: * birth weight ≤ 3rd percentile or ≥ 97th percentile for gestational age * have comorbid medical disorders including; those associated with sensorineural hearing loss, significant congenital anomalies, congenital heart disease, known brain injury/malformations * infants requiring mechanical ventilation * infants requiring continuous sedation
abx196 in combination with nivolumab in patients with hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of abx196 administered in combination with nivolumab in patients with hepatocellular carcinoma

this is an open-label, uncontrolled phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of abx196 administered in combination with nivolumab in patients with hepatocellular carcinoma. the study consists of 2 phases, a dose escalation phase and an expansion phase. nivolumab will be administered, consistent with the us prescribing information, as a 30-minute iv infusion on days 1 and 15 of each 28-day cycle. abx196 will be administered as an im injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on day 1 of every other 28-day cycle (i.e., every 8 weeks).

Eligibility criteria:
inclusion criteria: * men or women, age ≥18 years * patients with ecog performance status 0 or 1 * patients with histologically confirmed diagnosis of hcc not amenable to curative surgery or local therapy * patients with documented objective radiographic progression during or after local therapy or after treatment with sorafenib or lenvatinib or intolerance to or refusal to receive either agent * patients with at least one prior systemic therapy for hcc * patients eligible to be treated with nivolumab * patients with measurable disease based on recist v1.1 * patients with child-pugh class a liver score within 7 days of first study dose * patients with no history of hepatic encephalopathy * patients with no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible) * patients with hbv infection must have received antiviral therapy for at least 12 weeks and hbv viral load must be documented to be \<100 iu/ml within 7 days of first study dose * patients with no active co-infection with hbv and hcv or hbv and hdv * patients with no active drug or alcohol abuse exclusion criteria: * patients with tyrosine kinase inhibitor treatment within 2 weeks of first study dose * patients with esophageal or gastric variceal bleeding within the past 6 months * patients with portal vein invasion at the main portal (vp4) or the inferior vena cava or cardiac involvement of hcc based on imaging * patients with previous solid organ or hematologic transplantation * patients with active autoimmune disease requiring systemic treatment in the past 2 years * patients with diagnosis of immunodeficiency or receiving systemic steroid therapy or other immunosuppressive therapy within 7 days before first study dose * patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose * patients with minor surgery to liver or another site within 1 week before first study dose

Keywords: hcc nivolumab abx196
dexmedetomidine versus midazolam for peribulbar block

Conditions: Cataract

Summary: 50 patients of both sexes, ages 18 to 75, who were scheduled for cataract surgery and had physical status i or ii according to the american society of anesthesiologists were included in this study. after induction of general anesthesia, all patients received peribulbar block. in group a (midazolam group), 25 patients received midazolam. in group b (dexmedetomidine group), 25 patients received dexmedetomidine.

background: peribulbar blocks are commonly used for cataract surgery, providing effective anesthesia with reduced recovery time. the addition of sedative agents, such as dexmedetomidine or midazolam, may enhance the anesthetic effect and patient comfort while maintaining hemodynamic stability. however, the optimal sedative agent for use in this context remains uncertain. objective: this study aimed to compare the efficacy and safety of dexmedetomidine and midazolam as adjuvants to local anesthetic in peribulbar blocks for cataract surgery. methods: a randomized, double-blind clinical trial included 50 patients aged 18-75 years with the american society of anesthesiologists physical status i-ii who were scheduled for cataract surgery under peribulbar block. participants were randomly allocated to two groups: group a received midazolam (1 mg), and group b received dexmedetomidine (50 µg), combined with a standard mixture of local anesthetics. the primary outcomes included the onset and duration of motor and sensory block and lid akinesia. secondary outcomes assessed the quality of motor and sensory block, lid akinesia using the ocular anesthesia scoring system, sedation levels using the ramsay sedation score, the occurrence of local or systemic complications, and satisfaction levels reported by both patients and surgeons. keywords: dexmedetomidine; midazolam; peribulbar block; cataract surgery.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cataract disease * scheduled for cataract surgery * american society of anesthesiologists physical status i or ii. exclusion criteria: * history of allergy to any of the study medications * had impaired mental status * had coagulation abnormalities * had severe cardiac disease * had chronic obstructive lung disease * had a history of sleep apnea * refused to participate.

Keywords: dexmedetomidine midazolam peribulbar block cataract
patient safety learning laboratory: making acute care more patient-centered

Conditions: Central Line-Associated Bloodstream Infection (CLABSI); Venous Thromboembolism; Patient Fall; Catheter-Associated Infection; Severe Hypoglycemia; Opioid-Related Severe Adverse Drug Event; Hospital Acquired Pressure Ulcer; Adverse Drug Event; Severe Hospital Acquired Delerium; Rapid Response Related to Arrhythmia

Summary: the brigham and women's hospital (bwh) patient safety learning laboratory (psll) focuses on developing health information technology (hit) tools to engage patients, family, and professional care team members in reliable identification, assessment, and reduction of patient safety threats in real-time, before they manifest in actual harm.

the brigham and women's hospital (bwh) patient safety learning laboratory (psll) will develop systems approaches to integrating health information technology (hit), stakeholder engagement mechanisms, and process design/engineering methods focused on patient safety, development and enhancement of tools, health care system interventions, and translation into practice. the three technological toolkits to be developed as part of the patient safety learning laboratory (psll) are:1) patient-centered fall prevention toolkit which aims to engage patients and their family caregivers in the design of hit tools to prevent patient falls and related injuries during an acute hospitalization; 2) patient safety checklist tool to improve patient safety and quality outcomes, provider efficiency, and team communication; and 3) mysafecare patient safety reporting system which aims to iteratively develop and evaluate the impact of a patient safety reporting system on patient safety and fosters a health system focused on collaborative learning. the brigham and women's patient safety learning laboratory (bwh psll) will establish a vibrant learning ecosystem of health services, informatics, and systems engineering researchers, collaborating with patients and family for evolving and applying these approaches to adverse event prevention in hospitalized patients. in addition, a systems engineering, usability, and integration (seui) core will leverage health systems engineering approaches to develop and provide a system-wide methodology to aid in the successful implementation and improvement of health information technology (hit) tools and a model known as the patient satisfactive® will be developed, tested, and refined to create a culture of patient- and family-centered care.

Eligibility criteria:
inclusion criteria: * patients 18-99 years of age exclusion criteria: * patients under age 18 years
outcomes from treatment liver and bile duct diseases

Conditions: Benign or Malignant Liver and Bile Duct Disease

Summary: it is reported in the literature that the treatment of any liver and bile duct disease process, whether benign or malignant, continues to be a huge challenge. for example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. our goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity. the main aim of this study is to evaluate and compare the outcomes from our multiple treatments of benign or malignant liver and bile duct diseases.

the study will be a retrospective chart review of patients who have been diagnosed with benign or malignant liver and bile duct disease under the practices of rohan jeyarajah, m.d., houssam osman, m.d., f.a.c.s., edward cho, m.d., sc.m at methodist health system hospital in richardson, t.x. we plan to conduct an analysis of patients meeting the inclusion criteria form 2005 to present (up to the day before this study receives irb approval). charts will also be reviewed by the pi. sub-i, fellows, office staff, clinical research coordinator who are delegated to do so by the pi. data will be obtained from a national database. data will be analyzed primarily by the study conductors.

Eligibility criteria:
inclusion criteria: * all patients diagnosed and treated for liver and bile duct disease benign or malignant from 2005 to present (up to the day before this study receives irb approval) * age \> 18 years exclusion criteria: * patients that are not diagnosed with or treated for liver and bile duct disease * age \< 18 years
phase i trial of bay1251152 for advanced blood cancers

Conditions: Hematologic Neoplasms

Summary: the purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on blood cancer cells. once that safe dose is identified, additional patients will be asked to join the study to further evaluate the safety and effectiveness of the study drug. the study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide information about the effects of bay 1251152. the study will also measure some biological markers (markers of biological activity in your body) that can be used to predict the response and safety of the proposed treatment.


Eligibility criteria:
inclusion criteria: * male or female patients aged ≥18 years * eastern cooperative oncology group (ecog) performance status of 0 to 2 and life expectancy of at least 12 weeks * patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol * patients with confirmed advanced hematological malignancies * negative serum pregnancy test * women and men of reproductive potential must agree to use highly effective contraception when sexually active. * ability to understand and the willingness to sign a written informed consent. * patients must have adequate coagulation (international normalized ratio (inr) or prothrombin time (pt), partial thromboplastin time (ptt) ≤1.5 times uln) * adequate liver function (total bilirubin ≤ 1.5 times the uln, alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 2.5 times uln exclusion criteria: * presence of active/uncontrolled central nervous system involvement * history of clinically significant cardiac disease; uncontrolled hypertension * left ventricular ejection fraction (lvef) \< 45% * allogeneic stem cell transplant within 100 days before first dose of study drug * known history of human immunodeficiency virus (hiv) infection * chronic or active hepatitis b or c, requiring antiviral therapy * evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study * serious, uncontrolled infection * unresolved chronic toxicity \> grade 1 from prior therapy * use of strong cyp3a4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Keywords: phase 1 dose escalation dose expansion positive transcription elongation factor b inhibitor cyclin-dependent kinase 9 inhibitor